<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00284713</url>
  </required_header>
  <id_info>
    <org_study_id>TOPCARE-DCM</org_study_id>
    <nct_id>NCT00284713</nct_id>
  </id_info>
  <brief_title>Progenitor Cell Therapy in Dilative Cardiomyopathy</brief_title>
  <official_title>Transplantation Of Progenitor Cells And Recovery Of Left Ventricular Function In Patients With Nonischemic Dilatative Cardiomyopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johann Wolfgang Goethe University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johann Wolfgang Goethe University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intracoronary infusion of bone marrow derived progenitor cells into the LAD in patients with&#xD;
      non ischemic dilated cardiomyopathy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Initial clinical pilot trials suggested that intracoronary infusion of bone marrow-derived&#xD;
      progenitor cells (BMC) may enhance left ventricular functional recovery in patients with&#xD;
      acute myocardial infarction. It is unknown, however, whether such a strategy might also be&#xD;
      applicable to patients with non-ischemic dilated cardiomyopathy (DCM). Therefore, we&#xD;
      initiated the TOPCARE-DCM - trial (Transplantation Of Progenitor Cells And Recovery of Left&#xD;
      Ventricular Function in Patients with non ischemic Dilatative CardioMyopathy) aiming to&#xD;
      regionally improve left ventricular contractility by selective infusion of BMC into the left&#xD;
      anterior descending coronary artery.&#xD;
&#xD;
      Patients will be randomized 2:1 (20/10) BMC Infusion versus standard medical therapy&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>LV function (Ejection fraction within 3 months) Simpson</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Heart Failure, Congestive</condition>
  <condition>Cardiomyopathy, Dilated</condition>
  <condition>Stem Cell Transplantation</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>intracoronary infusion of BMC</intervention_name>
    <description>catheter delivery of stem cells</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 8-80&#xD;
&#xD;
          -  Dilated Cardiomyopathy, Ejection fraction &lt; 40%&#xD;
&#xD;
          -  LVEDD &gt; 60mm&#xD;
&#xD;
          -  Stable clinical condition within last 6 months&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Myocardial infarction or coronary intervention in the past&#xD;
&#xD;
          -  Change of medical therapy within the last 6 weeks prior to cell therapy&#xD;
&#xD;
          -  Tumor within last 5 years or incomplete remission&#xD;
&#xD;
          -  Active infection&#xD;
&#xD;
          -  Active bleeding&#xD;
&#xD;
          -  Stroke within last 2 years&#xD;
&#xD;
          -  Surgery or trauma within last 2 months&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  HIV infection&#xD;
&#xD;
          -  Chronic inflammatory disease&#xD;
&#xD;
          -  Liver disease (GOT &gt; 2x upper normal limit)&#xD;
&#xD;
          -  Renal dysfunction (creatinin &gt; 2.0mg/dl)&#xD;
&#xD;
          -  Thrombopenia &lt; 100.000&#xD;
&#xD;
          -  Anemia (hemoglobin &lt; 8.5 g/dl)&#xD;
&#xD;
          -  Mental retardation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas M Zeiher</last_name>
    <role>Principal Investigator</role>
    <affiliation>Div. of Cardiology, University of Frankfurt, Germany</affiliation>
  </overall_official>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <verification_date>February 2009</verification_date>
  <study_first_submitted>January 31, 2006</study_first_submitted>
  <study_first_submitted_qc>January 31, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2006</study_first_posted>
  <last_update_submitted>February 17, 2009</last_update_submitted>
  <last_update_submitted_qc>February 17, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2009</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Cardiomyopathy, Dilated</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

